Computational and Mathematical Methods in Medicine-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2022-04-15 ms5000001929075945

录用快，大概两个月左右

94 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2022-01-08 ms8000001921292606

偏重的研究方向：生信
经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审

54 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2020-10-27 两难不难

7.10投稿 10.26接收。编辑很客气。

126 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2022-09-10 ms4000000947619634

这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑

55 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2022-09-22 ms8000000524560535

被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录

57 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2022-07-31 147a477am62(暂无昵称)

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：乳腺癌
经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。

100 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2022-10-29 ms5000001211895712

reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊

53 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2022-08-13 ms7000000865881183

各位大佬，网络药理学可能投哪个主题的特刊

85 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2022-06-29 ms6000002031408843

请问该期刊接收纯网药➕分子对接的文章吗？

4 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1211474, encodeId=ac8712114e48d, content=录用快，大概两个月左右, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=08a98117772, createdName=ms5000001929075945, createdTime=Fri Apr 15 16:27:08 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182242, encodeId=a870118224294, content=偏重的研究方向：生信 经验分享：请问投稿一个月了还没分配学术编辑这个是正常的嘛说明现在文章是不是还在责任编辑那内审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe0e5623045, createdName=ms8000001921292606, createdTime=Sat Jan 08 16:20:15 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894888, encodeId=07ff89488838, content=7.10投稿 10.26接收。编辑很客气。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/5888f6640265430b902b3fded856f491/788d7d25b2f7419ab0fab8df4239cea1.jpg, createdBy=c0775397989, createdName=两难不难, createdTime=Tue Oct 27 18:04:44 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248263, encodeId=3d9e1248263b0, content=这个杂志，文章接收了，版面费交了，然后不给proof，不给见刊出版，真的坑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=06375534862, createdName=ms4000000947619634, createdTime=Sat Sep 10 10:17:44 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2089719, encodeId=95cf2089e1981, content=被Hindawi其他杂志拒绝了，还能投这个吗？编辑是否能看到之前的记录, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c31b6158531, createdName=ms8000000524560535, createdTime=Thu Sep 22 09:39:23 CST 2022, time=2022-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1235766, encodeId=68fd1235e6642, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：乳腺癌 经验分享：1天就ae assign还以为效率高，结果这个叫alagar karthick的ae通过publication2k21@gmail.com给我发邮件让我通过一个私人WhatsApp联系他，离了大谱。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=100, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4e325232943, createdName=147a477am62(暂无昵称), createdTime=Sun Jul 31 13:47:07 CST 2022, time=2022-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2097337, encodeId=0df8209e33746, content=reviewers invited 快俩月了一直不动发邮件回复说两周找一次审稿人还没找到。这要到啥时候啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=53, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fa25623499, createdName=ms5000001211895712, createdTime=Sat Oct 29 19:32:36 CST 2022, time=2022-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238508, encodeId=724c123850809, content=各位大佬，网络药理学可能投哪个主题的特刊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11aa5449749, createdName=ms7000000865881183, createdTime=Sat Aug 13 18:07:12 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1229465, encodeId=7323122946517, content=请问该期刊接收纯网药➕分子对接的文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c005725575, createdName=ms6000002031408843, createdTime=Wed Jun 29 14:28:33 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809531, encodeId=77bb8095318b, content=有一篇纯生信送到我手上了（笑）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=135, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/05/991da29bc4331ab8e918449e7a4184aa.jpg, createdBy=3ffc2393635, createdName=机智肝帝武运昌隆欧洲呆, createdTime=Sun Aug 16 23:58:04 CST 2020, time=2020-08-16, status=1, ipAttribution=)]

2020-08-16 机智肝帝武运昌隆欧洲呆

有一篇纯生信送到我手上了（笑）

135 7

展开7条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务